Product News
Filter News
Found 274,496 articles
-
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4/22/2024
Legend Biotech Corporation announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on the last therapy and are refractory to lenalidomide.
-
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
4/22/2024
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
-
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
4/22/2024
ImmunoPrecise Antibodies Ltd. has recently announced an expansion of its already successful LENSai TM Platform.
-
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
4/22/2024
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections.
-
Cytonus Therapeutics Expands C-suite as it Transitions to a Clinical Stage Company
4/22/2024
Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.
-
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
4/22/2024
Kintor Pharmaceutical Limited announced that the China phase II clinical trial of its in-house developed first-in-class androgen receptor proteolysis targeting chimera compound GT20029 tincture for the treatment of male androgenetic alopecia has reached the primary endpoint, with statistically significant and clinically meaningful results, as well as good safety and tolerability.
-
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
4/22/2024
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.
-
Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB(R) to Enable Autologous Blood Transfusions in Cancer Surgeries
4/22/2024
Lindis Blood Care announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
-
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
4/22/2024
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.
-
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
4/22/2024
Natera, Inc. today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
-
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
4/22/2024
IDEAYA Biosciences, Inc. announced selection of a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, based on adverse event profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1.
-
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
4/22/2024
Lantern Pharma Inc. announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer.
-
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
4/22/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date.
-
Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems
4/22/2024
Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
-
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
4/22/2024
Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, provided an update on the clinical development of its lead asset, rupitasertib, a selective oral inhibitor of S6K and AKT1/AKT3.
-
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
4/22/2024
FSD Pharma Inc provides an update by way of a news release issued by Celly Nutrition Corp. and its launching of unbuzzd, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.
-
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
4/22/2024
Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19.
-
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
4/22/2024
Kura Oncology, Inc. today announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).
-
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
4/22/2024
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.
-
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
4/22/2024
Quest Diagnostics today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.